NASDAQ: LUNG
October 2023
© 2023 Pulmonx Corporation | 1 |
Forward Looking Statement
This presentation and certain statements made during this presentation contain forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including any statements regarding our ability to design, develop, manufacture and market innovative products to treat patients with challenging medical conditions, particularly those with chronic obstructive pulmonary disease (COPD) and emphysema; our expectations regarding the impact of the COVID-19 pandemic on our business; our expected future growth of our company; the size and growth potential of the markets for our products, and our ability to serve those markets; any projections of financial information, market opportunities, profitability, or financial position; the rate and degree of market acceptance of our products; coverage and reimbursement for procedures performed using our products; our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines; our plans to research, develop and commercialize our products and any other approved or cleared product; our ability to retain and hire our senior management and other highly qualified personnel; the development, regulatory approval, efficacy and commercialization of competing products; our future financial performance and capital requirements; information including the anticipated efficiencies and strategic and financial benefits related to our products; and our expectations regarding our ability to obtain and maintain intellectual property protection for our products are forward-looking statements. The words "may," "will," "should," "expect," "plan," "anticipate," "could," "would," "intend," "target," "project," "estimate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that could cause actual results to differ materially from those contemplated in this presentation can be found in the Risk Factors section of Pulmonx's public filings with the Securities and Exchange Commission ("SEC"), including the Quarterly Report on Form 10-Q filed with the SEC on August 4, 2023, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in the Company's business.
© 2023 Pulmonx Corporation | 2 |
Investment Highlights
Large Market
$12B opportunity for severe
emphysema
Precision Treatment
Proprietary patient selection
technology & minimally invasive
treatment
Consistent Clinical Results
Clinical benefits demonstrated
across 4 RCTs
100+ scientific publications
Broadly Reimbursed
In global guidelines & reimbursed
in US, Europe and Australia
Global Footprint
>25,000 patients treated
in >25 countries
Strong Pipeline & Team
Additional technology to expand
market, experience to deliver
© 2023 Pulmonx Corporation | 3 |
COPD and Emphysema:
A Prevalent Disease with High Unmet Medical Needs
- Emphysema: a form of Chronic Obstructive Pulmonary Disease (COPD) resulting in the progressive destruction of lung tissue
- Accounts for ~25% of all COPD patients1
- Air-trappingincreases lung volume and persistent breathlessness
- COPD among the leading causes of death worldwide
Emphysema Disease Progression
- Hyperinflation
Short of
Breath
- Activity
Deconditioning &
- Breathlessness
- Activity
Deconditioning & Breathlessness
High Risk of Mortality
© 2023 Pulmonx Corporation 1 Approximately 16M COPD patients in the U.S. as of 2013; approximately 3.8M emphysema patients and 1.5M severe emphysema patients in the U.S. as of 2018. | 4 |
Spectrum of Treatment Options
Medical | Pulmonary | Zephyr® Valves | Lung Volume | Lung |
Management | Rehabilitation | Reduction Surgery | Transplant | |
Non-invasive | Non-invasive | Designed to Provide | Invasive | Invasive |
Limited effect in | Difficult to sustain | Benefits Similar to | Effective | Effective |
Surgery with Broader | >5% risk of death | 5-15% risk of death | ||
severe patients | benefits | |||
Eligibility | ||||
Not an option for most | Not an option for most | |||
Minimally Invasive | patients | patients |
Fully Removable
© 2023 Pulmonx Corporation | 5 |
How Zephyr® Valves Work
1 | 2 | 3 |
Bronchoscope introduced into lungs | Delivery catheter advanced into | Valve size chosen in one step procedure |
of patient with diseased, hyperinflated lobe | target lobe through bronchoscope | and delivered to seal target airway |
4 | 5 | 6 |
Zephyr® Valve allows trapped | An average of 4 Zephyr® Valves | Hyperinflation in target lobe is reduced, |
air to escape but not to re-enter | delivered to fully occlude diseased lobe | improving lung function and breathlessness |
© 2023 Pulmonx Corporation | 6 |
The Zephyr Valve Patient Journey
Standard COPD | StratX® Report | Chartis® | Zephyr® Valves | 3 Night |
Work Up | Assessment | Placed | Stay | |
Patient undergoes standard pulmonary work up, including pulmonary function testing and CT scan
CT scan uploaded to cloud, generating report to help identify one or more eligible lobes for treatment
Patient sedated & Chartis® procedure simulates valve placement with a balloon catheter in target lobe(s) to test for collateral ventilation
Bronchoscopic placement of Zephyr® Valves in less than an hour procedure
Patient remains in the hospital for monitoring for a minimum of 3 nights following the procedure
© 2023 Pulmonx Corporation | 7 |
Collateral Ventilation: A Key Exclusion Criteria
No Collateral Ventilation (CV-) | Collateral Ventilation (CV+) |
✓Complete lobar | Incomplete lobar |
fissures | fissures |
✓Normal air | Bypassing of |
passage | normal airways |
✓Eligible for | ~50% of severe |
procedure | emphysema |
patients |
Patient Screening is Critical for Optimal Patient Selection
© 2023 Pulmonx Corporation | 8 |
StratX® Analysis Helps Determine Eligible Lobes
CT Scan | StratX Report |
Cloud Upload
- Cloud-basedquantitative analysis of CT Scan
- First line evaluation for:
- Volume
- Tissue Destruction
- Fissure completeness - an indicator for collateral ventilation
- Identifies potential lobe(s) for Chartis® Evaluation and Zephyr® Valve treatment
© 2023 Pulmonx Corporation | 9 |
Chartis® System: Proprietary CV Testing for
Patient Eligibility
Physiological Measure of Collateral
Ventilation
- Evaluates the presence or absence of collateral ventilation
- Measures changes in pressure and airflow
- Unique, patent protected technology
© 2023 Pulmonx Corporation | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Pulmonx Corporation published this content on 30 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 October 2023 20:33:26 UTC.